First-line therapeutic strategies in metastatic colorectal cancer.

摘要: The treatment of metastatic colorectal cancer (mCRC) has changed dramatically from the 1980s, when only fluorouracil (5-FU) was available for and median survival at best 12 months, to a time mCRC is considered more chronic disease in which now reported excess 2 years. This review traces evolution this setting, including studies single-agent vs combination with 5-FU/leucovorin, irinotecan, oxaliplatin, capecitabine, comparisons simultaneous sequential regimens, role targeted agents such as bevacizumab, cetuximab, panitumumab.